Aarti Pharmalabs Limited has informed the Exchange about Re-appointment of Cost Auditor & Internal Auditor for FY 2026-2027

Net loss reportedEBITDA margin compressionExceptional itemResults restatedResults View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹732.10

prior close

₹706.80

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-5.8% vs market

Pharmaceuticals peers, median of 165sector+0.2%-5.3% vs sector

On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+0.0

15m

+0.6

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.7-5.8+0.2-5.3

Next day

-10.5+0.7-11.2-0.1-10.4

-11.6+0.0-11.7-0.3-11.3

-12.4-1.1-11.3-1.3-11.0

-13.1+0.0-13.1-1.2-11.9

-15.0+0.3-15.3-1.5-13.5

-14.0+1.1-15.1-0.6-13.4

15d

-11.8+4.9-16.6-0.3-11.5

-7.3+5.3-12.7+3.1-10.4

-6.7+6.9-13.6+4.1-10.8

+14.6+11.9+2.7+7.1+7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs reported standalone net profit of Rs 17,620.20 lakhs for FY2026, down 31.5% from Rs 25,734.88 lakhs in FY2025 despite relatively flat revenue of Rs 179,755.17 lakhs (up 1.5% YoY). Consolidated revenue declined 14% to Rs 181,944.25 lakhs due to Ganesh Polychem becoming a joint venture from April 2025, making prior period numbers non-comparable. Finance costs nearly doubled to Rs 4,690.08 lakhs, significantly impacting profitability. The Board declared a final dividend of Rs 2 per share (40% on Rs 5 face value). An exceptional item of Rs 279.49 lakhs was recorded for new labour codes provision. The Q3 FY2025-26 figures were restated due to a previously omitted forward contract fair value impact of Rs 2,972.94 lakhs, which has now been recognized. Cost Auditor Smt. Ketki D. Visariya and Internal Auditor Manish Modi & Associates were reappointed for FY2026-27.

Likely market impact

Significant PAT decline of 31.5% YoY with near-doubling of finance costs signals margin pressure and higher debt servicing costs. The restatement of Q3 figures due to derivative accounting errors may raise concerns about internal controls. However, the unmodified audit opinion and continuation of dividend provide some comfort.